Presentation is loading. Please wait.

Presentation is loading. Please wait.

UC Care Ltd. Proprietary May 151UC Care Ltd. Proprietary Prostate Smart Biopsy solutions Enabling tools for Active Surveillance and Focal therapy of Prostate.

Similar presentations


Presentation on theme: "UC Care Ltd. Proprietary May 151UC Care Ltd. Proprietary Prostate Smart Biopsy solutions Enabling tools for Active Surveillance and Focal therapy of Prostate."— Presentation transcript:

1 UC Care Ltd. Proprietary May 151UC Care Ltd. Proprietary Prostate Smart Biopsy solutions Enabling tools for Active Surveillance and Focal therapy of Prostate cancer Navigo™ and SmartBx™

2 UC Care Ltd. Proprietary May 152UC Care Ltd. Proprietary The Navigo™ is a high accuracy Biopsy system enabling: 3D real-time biopsy navigation and recording Improved PCa detection Accurate Active Surveillance (AS) Planning of focal therapy Navigo™ System by UC-Care

3 UC Care Ltd. Proprietary May 153UC Care Ltd. Proprietary 1.Accurate positioning based on an advanced “local GPS” 2.Insensitive to patient’s movements (critical in non-anesthetized patients) 3.Providing a 3D model of the prostate (based on 2D US) 4.Real-time monitoring of biopsy needle image on 3D model 5.Registration of previous and current procedures (“return to point”) 6.Connects to existing ultrasound systems (End fire, Side fire) 7.Archiving the ultrasound images, biopsies location on the 3D model and pathology reports (recording of the entire procedure) 8.Providing data management solutions 9.Offline/office playback capabilities 10.Patient report including biopsies location on the 3D model 11.Minimal change to current biopsy setup The Navigo™- Technical Capabilities

4 UC Care Ltd. Proprietary May 154UC Care Ltd. Proprietary 1.Requires no change in current TR biopsy procedure 2.Real time monitoring of previously taken biopsies alongside current trajectory, enabling systematic distribution 3.Real time monitoring of needle trajectory location from different points of view 4.Enabling biopsy taken from ROI 5.No lost Data, accumulation of data from sequential Transrectal procedures (accumulated saturated biopsy) 6.In-office planning, and data management capabilities ( for repeat Bxs, treatment) 7.Complete procedure recording 8.Minimal training The Navigo™ Clinical benefits

5 UC Care Ltd. Proprietary May 155UC Care Ltd. Proprietary 3D model of the prostate with biopsy location Navigo System™

6 UC Care Ltd. Proprietary May 156UC Care Ltd. Proprietary Problems & challenges: Detection reduced by: - - Small fragments may be lost - Not-in-plane cutting of specimen - Multiple core entanglement Cancer localization - Head- tail orientation - Short cores location (core may be much shorter than needle notch). - Location of cancer within the core SmartBx™- Specimen treatment Biopsy cores entangled in a paraffin block using current methods

7 UC Care Ltd. Proprietary May 157UC Care Ltd. Proprietary The core is directly downloaded on a cassette, preserving the specimen location and orientation as on the needle notch Several cores may be separately placed, in parallel on the same plane, in a cassette (no entanglement) The specimens on the cassette is there-on handled by the regular pathology lab process. ( Fixation, Paraffin blocking, etc.) The SmartBx™ solution advantages - Simple handling - Potentially Improved detection (the entire volume is kept) - A - Accurate localization for detected cancer within specimen SmartBx™ solution

8 UC Care Ltd. Proprietary May 158UC Care Ltd. Proprietary The SmartBx™ solution – summery: Semi-automated collection of the specimen. Collection of the entire core volume including fragments. Straightened cores with minimal distortion. Compatible and integrated into current routine Path-lab. Process. In-specimen P.Ca location Registry of biopsy numbering, Cancer location, pathologic features. SmartBx™

9 UC Care Ltd. Proprietary May 159UC Care Ltd. Proprietary Improved PCa detection SmartBx™Improved detection of clinically significant PCa on 1 st biopsy due to better spatial biopsies distribution and SmartBx™ SmartBx™Improved detection of clinically significant PCa on repeated biopsy due to data from previous sessions and SmartBx™ Providing the tools needs for Active Surveillance Reducing number of biopsies (procedures and cores) Saturation biopsy performance achieved by accumulation of standard biopsies data Clinical advantage

10 UC Care Ltd. Proprietary May 1510UC Care Ltd. Proprietary Lost Data  Study performed for detecting PCa in patients having high PSA Prostate biopsy: who, how and when. Can J Urol Feb; Djavan B  Cancer detection rates on first, second, third and fourth biopsy were – 22% (231/1051), 10% (83/820), 5% (36/737) and 4% (4/94), respectively Calculation of lost data in repeat biopsy procedures:  Total number of Bx procedures performed: 2702  Total number of procedures without P.Ca. detection (i.e.- were data is not available for repeated Bx) : In more than 83% of procedures the data from previous procedures cannot be used to guide the new biopsies - Per each session, the non-accumulated data loss is 78%,90%, 95%, and 96% ( 1 st to 4 th procedures, in correlation) The Navigo™ saves the biopsy data for future reference and use

11 UC Care Ltd. Proprietary May 1511UC Care Ltd. Proprietary  THANK YOU


Download ppt "UC Care Ltd. Proprietary May 151UC Care Ltd. Proprietary Prostate Smart Biopsy solutions Enabling tools for Active Surveillance and Focal therapy of Prostate."

Similar presentations


Ads by Google